Status:
COMPLETED
Visualizing Dermal Micropores With OCT
Lead Sponsor:
University of Iowa
Conditions:
Healthy
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
The study to be performed will allow visualization of skin micropores following microneedle treatment in healthy subjects in differing racial/ethnic backgrounds.
Detailed Description
Transdermal drug delivery (by way of patches that adhere to the skin and deliver drug in a time-dependent fashion) allows for systemic drug delivery through the skin, while avoiding many of the side e...
Eligibility Criteria
Inclusion
- Subjects will be healthy men and women between 18 and 45 years of age.
Exclusion
- Unable to give consent
- Severe general allergies requiring chronic treatment with steroid or antihistamines
- Previous adverse reaction to microneedle insertion
- History of keloids
- Known allergy or adverse reaction to medical tape/adhesive, or aloe vera
- Any inflammatory diseases of the skin (including but not limited to: psoriasis, atopic dermatitis, and blistering skin disorders)
- Any disease associated with altered immune function (including but not limited to: rheumatoid arthritis, diabetes, lupus, HIV/AIDS)
- Any subject taking medication that impairs the immune system (including but not limited to corticosteroids, TNF inhibitors, monoclonal antibodies, chemotherapy agents)
- Any current malignancy or history of malignancy present at the treatment sites
- Eczema or scaling present at any treatment site; any current inflammation or irritation present at the treatment sites (including but not limited to: rash, inflammation, erythema, edema, blisters)
- Uncontrolled mental illness that would, in the opinion of the investigator, affect the subject's ability to understand or reliably participate in the study
- Subjects taking medications in the following therapeutic classes will be excluded: HMGCoA reductase inhibitors ("statins"), oral or topical steroids (at the local treatment site), oral antibiotics, topical antibiotics at the local treatment site, topical antihistamines at the local treatment site, beta-blockers, and systemic or topical NSAIDS/analgesics. A subject who has recently used oral or topical steroids, antibiotics, antihistamines, or analgesics may be enrolled if more than 5 elimination half-lives of the drug have passed since the last dose (this is a typical parameter in pharmacokinetics, when it is assumed that \~97% of drug in the systemic circulation is eliminated after 5 half-lives). The estimated elimination half-life for any specific drug will be obtained from standard pharmacy references such as Micromedex or other comparable drug information references.
- Any subjects that are pregnant/nursing will be excluded from participation.
- Subjects will also be excluded for any condition that would, in the opinion of the PI or physician, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.
Key Trial Info
Start Date :
April 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 29 2022
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT04867733
Start Date
April 1 2021
End Date
June 29 2022
Last Update
May 28 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Iowa
Iowa City, Iowa, United States, 52242